This video segment profiles a 72-year-old retired science teacher with multiple myeloma, detailing his treatment journey from VRd induction and ASCT to relapse, management of comorbidities, and receiving cilta-cel, supported by his active and healthy wife.
This segment highlights the treatment journey of a 68-year-old IT professional with high-risk multiple myeloma, detailing progression after initial D-RVd therapy, refusal of ASCT, and successful transition to cilta-cel CAR-T therapy with manageable adverse events.
The conversation examines adverse events beyond CRS and neurotoxicities in CAR-T therapy, focusing on strategies for managing prolonged cytopenias, infection prophylaxis, and unique adverse events associated with ide-cel and cilta-cel.
Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE profiles of talquetamab, teclistamab, and elranatamab, highlighting unique challenges and benefits.
Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on preventive measures and comparisons with GI management strategies for other EGFR inhibitors.
Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, discussing unique challenges and benefits observed in clinical practice.
Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, highlighting multidisciplinary management strategies and integrating best practices into electronic medical records.
Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including preventive measures and comparisons to managing GI issues from other EGFR inhibitors.
Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.
The discussion focuses on monitoring and managing neurologic toxicities like ICANS in CAR-T therapy, highlighting tools for early detection, effective management strategies, and approaches to communicating risks with patients and caregivers.
Expert panelists explore approaches to grading and managing Cytokine Release Syndrome (CRS) in CAR-T therapy, discussing effective strategies to mitigate severity and key differences in CRS management protocols between ide-cel and cilta-cel.
This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle support, balancing work during and after treatment, and effective supportive care measures.
This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting monitoring strategies, tools for early detection, and approaches to communicating risks with patients and caregivers.
Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due to adverse events (AEs), including experiences where these adjustments significantly impacted patient outcomes.
Dr. Mohan discusses with Nurse Goff and Nurse Brigle the prevention and management of infections and neurological toxicities in patients receiving bispecific therapies, with a particular focus on the unique considerations of talquetamab targeting GPRC5D.
An expert discussion surrounding experience with managing weight gain and gastrointestinal adverse events associated with lorlatinib, addressing quality of life, symptom mitigation strategies, and maintaining treatment efficacy.
Key opinion leaders discuss strategies for managing neurotoxicity with lorlatinib and other ALK inhibitors, including monitoring adverse events and balancing symptom management with treatment efficacy.
Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, highlighting strategies to address quality-of-life impacts while maintaining the benefits of treatment.
Strategies for managing cardiotoxicity in patients on osimertinib are discussed, focusing on monitoring adverse events and balancing symptom management with maintaining treatment efficacy.
Erica S. Doubleday, MS, FNP-C, BSN, RN, outlined upcoming approvals and care options for providers to expect in the breast cancer space.
La-Urshalar Brock, FNP-BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in patients with breast cancer.
Susumu Hijioka, MD, discussed how a lower dose of everolimus may help address certain adverse events like oral mucositis and hypoglycemia.
Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that patients and caregivers fully understand their choices and make informed decisions.
Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that patients and caregivers fully understand their choices and make informed decisions.
Panelists discuss resources and strategies to help patients and caregivers cope with the initial shock of a paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, emphasizing critical points during the first consultation, and explore how Brandi communicated her treatment preferences to her care team, reflecting on her sense of inclusion in the decision-making process and areas for improvement.
Medical experts discuss strategies for educating patients on managing side effects of osimertinib and other EGFR inhibitors, with guidance on recognizing symptoms that warrant contacting their care team.
Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.
Medical experts discuss strategies for patient education on managing potential adverse events of lorlatinib and other ALK inhibitors, emphasizing what to expect and when to contact the care team.
